• English
  • Eesti

Heads of EU Medicines Agencies meet in Tallinn to discuss the priorities of the medicines sector

Printer-friendly version

The meeting of the network of the Heads of Medicines Agencies (HMA) as steered by the Estonian State Agency of Medicines (SAM) will start tomorrow, on 5 September.

The meeting brings together 100 delegates to discuss issues raised by the SAM as part of Estonian Presidency of the Council of the EU. The Director General of the SAM Kristin Raudsepp outlined the essentials: “The meeting will focus on actual and critical issues as well as address any future requirements. The focal point is the availability of medicines, including innovation and the availability of new medicinal products, and implementing the new regulation on clinical trials. Also, we will address in detail the availability of veterinary vaccines. Further topics include the strengthening of surveillance to exclude counterfeit medicines from legal supply chain, and implementing the safety features. We will talk about the possibilities for optimising regulatory activities, incl. the development of e-services and enhancing cooperation within the network of medicines agencies. Furthermore, the agenda features other issues of strategic importance like the impact of Brexit on surveillance activities and services of the Member States’ medicines agencies. In addition, an overview of developments related to the regulation on veterinary medicines will be provided.” 

The meeting will take place on 5-7 September at the Radisson Blu Hotel Olümpia in Tallinn.

For more information on the HMA working group please visit our website.